Table 3 Summary of TEAEs during the LTE (safety population)a

From: Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease

 

LTE safety population (N = 33)

Participants with ≥1 AE, n (%)

31 (93.9)

Mild

13 (39.4)

Moderate

17 (51.5)

Severe

1 (3.0)

Participants with ≥1 treatment-related AE, n (%)

14 (42.4)

Mild

5 (15.2)

Moderate

8 (24.2)

Severe

1 (3.0)

Participants with ≥1 procedure-related AE, n (%)

24 (72.7)

Mild

15 (45.5)

Moderate

9 (27.3)

Severe

0

Participants with ≥1 serious AE, n (%)

4 (12.1)

Participants with ≥1 treatment-related serious AE, n (%)

0

Participants with ≥1 procedure-related serious AE, n (%)

0

Participants with ≥1 AE leading to discontinuation of BIIB080, n (%)

3 (9.1)

  1. AE, adverse event.
  2. a The LTE safety population included all participants who were randomized and received ≥1 dose of BIIB080.